TY - JOUR
TI - Eplerenone in the treatment of central serous chorioretinopathy: A review of the literature
AU - Chatziralli, I.
AU - Vlachodimitropoulou, A.
AU - Daoula, C.
AU - Vrettou, C.
AU - Galani, E.
AU - Theodossiadis, G.
AU - Theodossiadis, P.
JO - International Journal of Retina and Vitreous
PY - 2018
VL - 4
TODO - 1
SP - null
PB - BioMed Central Ltd.
SN - 2056-9920
TODO - 10.1186/s40942-018-0137-8
TODO - eplerenone;  mineralocorticoid receptor;  spironolactone, central serous retinopathy;  diabetes mellitus;  drug absorption;  drug efficacy;  drug safety;  drug tolerability;  follow up;  heart failure;  human;  hyperkalemia;  kidney failure;  pathophysiology;  retinal pigment epithelium;  Review;  systematic review;  visual acuity
TODO - Purpose: The purpose of this review is to examine the role of eplerenone in the treatment of central serous chorioretinopathy (CSCR). Methods: A comprehensive search of the PubMed database has been conducted regarding eplerenone for CSCR, while studies using spironolactone were excluded. Articles and book chapters cited in the reference lists of articles obtained by this method were reviewed and included when considered appropriate, while the retrieved articles were filtered manually to exclude duplicates. Results: Oral eplerenone at a dose of 25-50 mg/day has been found to be effective and well-tolerated for the treatment of chronic CSCR. The published studies have shown significant improvement in visual acuity and decrease or total absorption of subretinal fluid in patients with CSCR treated with oral eplerenone. However, it should be noted that the majority of studies were retrospective with limited number of patients and short follow-up. On the other hand, patients presenting widespread retinal pigment epithelium changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention. Conclusions: CSCR is a challenging disease to understand and treat, since its pathogenesis remains elusive and multifactorial. Pharmacologic approaches, like eplerenone, are intriguing, as they target several pathophysiological pathways and may lead to visual acuity improvement and more rapid recovery. © The Author(s) 2018.
ER -